Advances in the Management of HPV-Related Oropharyngeal Cancer

Immune check-point in cervical cancer

(2018) F. De Felice et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management

(2018) F. De Felice et al.   ORAL ONCOLOGY

Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review

(2018) Francesca De Felice et al.   NEOPLASIA

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

(2018) T Y Seiwert et al.   ANNALS OF ONCOLOGY

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

(2018) Hisham Mehanna et al.   LANCET

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

(2018) Maura L Gillison et al.   LANCET

Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer

(2017) John D. Cramer et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Two-Year Results for MC1273, a Phase 2 Evaluation of Aggressive Dose De- Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma (OPSCC)

(2017) D.J. Ma et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Personalized Approach Using Hypoxia Resolution to Guide Curative-Intent Radiation Therapy Dose-Reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-Associated Oropharynx Cancers Treated With Concurrent Chemoradiation Therapy

(2017) N. Riaz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later

(2017) Shao Hui Huang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

(2017) Shanthi Marur et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study

(2017) Allen M Chen et al.   LANCET ONCOLOGY

Appraisal of the AJCC 8th edition pathologic staging modifications for HPV−positive oropharyngeal cancer, a study of the National Cancer Data Base

(2017) Kevin Y. Zhan et al.   ORAL ONCOLOGY

Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy

(2017) Sandro V Porceddu et al.   ORAL ONCOLOGY

Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control

(2017) Daan Nevens et al.   RADIOTHERAPY AND ONCOLOGY

Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus–Related Oropharyngeal Carcinoma

(2016) Nancy Lee et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

(2016) Brian O'Sullivan et al.   LANCET ONCOLOGY

Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx

(2016) B.H. Haughey et al.   ORAL ONCOLOGY

Osteoradionecrosis following treatment for head and neck cancer and the effect of radiotherapy dosimetry: the Guy's and St Thomas' Head and Neck Cancer Unit experience

(2016) Francesca De Felice et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma

(2015) Bhishamjit S. Chera et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Analysis of loco-regional failures in head and neck cancer after radical radiation therapy

(2015) Francesca De Felice et al.   ORAL ONCOLOGY

International trends in head and neck cancer incidence rates: Differences by country, sex and anatomic site

(2014) Edgar P. Simard et al.   ORAL ONCOLOGY

Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer

(2013) Allen M. Chen et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers

(2013) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity

(2013) Sandra Nuyts et al.   RADIOTHERAPY AND ONCOLOGY

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

(2011) Christopher M Nutting et al.   LANCET ONCOLOGY

The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial

(2011) Pernille Lassen et al.   RADIOTHERAPY AND ONCOLOGY

Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck

(2009) Pernille Lassen et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY